ArticleFrontiers in immunology2025
Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The outcomes of coronavirus disease 2019 (COVID-19) in patients with bullous pemphigoid (BP) remain insufficiently understood. This study aimed to evaluate the impact of COVID-19 on BP patients and identify factors influencing the risk and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in BP patients. Methods: A cross-sectional survey was conducted among BP patients in the Department of Dermatology at Shanghai Skin Disease Hospital from December 1, 2022, to March 1, 2023. Participants completed a comprehensive questionnaire addressing demographics, medical conditions, clinical symptoms, and behaviors during the COVID-19 pandemic. Factors influencing the risk of SARS-CoV-2 infection and its severity were evaluated by logistic regression. Results: A total of 96 BP patients were analyzed. Demographic and clinical profiles, COVID-19-related characteristics, and the pandemic's impact on healthcare-seeking behaviors were described. Our findings showed that vaccination was associated with a reduced risk of SARS-CoV-2 infection (odds ratio [OR]: 0.157, 95% confidence interval [CI]: 0.045-0.552, p=0.002) and infection severity (OR: 0.044, 95% CI: 0.004-0.544, p=0.015). Furthermore, the use of prednisone at a dose >10 mg/day in the last 3 months was associated with an increased risk of SARS-CoV-2 infection (OR: 7.911, 95% CI: 1.379-45.393, p=0.012) but did not appear to influence infection severity. Conclusions: The COVID-19 pandemic posed significant challenges for BP patients. Our study found that the use of prednisone at a dose >10 mg/day in the last three months was associated with an increased risk of SARS-CoV-2 infection. Vaccination provided protection against SARS-CoV-2 infection and severe COVID-19 in BP patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.